Applications of Liposome Technology to Overcome Multidrug Resistance in Solid Tumors

  • Rajesh Krishna
  • Lawrence D. Mayer
Chapter
Part of the NATO ASI Series book series (NSSA, volume 300)

Abstract

A significant obstacle to chemotherapy of many human malignancies is the development of drug resistance. Multidrug resistance (MDR) is defined as the ability of tumor cells to develop resistance to the cytotoxic effects of a variety of chemically unrelated chemotherapeutic agents. Several mechanisms have been proposed to explain this phenomenon; however, the P-glycoprotein (PGP) based MDR phenotype has received the most attention and has been correlated with poor patient outcome for a number of tumor types. Conventional strategies employed for overcoming MDR involve the use of a PGP inhibitor coadministered with the anticancer agent. However, progress in this area has been hindered by the relatively low specificity of PGP modulators for tumor tissue. This has resulted in problems associated with inherent modulator toxicity as well as modulator induced changes in anticancer drug pharmacokinetics. Several avenues have been pursued using liposome technology to overcome these difficulties. This review summarizes some of the work done in this area and how long circulating non-leaky liposomes may be applied to circumvent adverse drug-drug interactions between MDR modulators and anticancer drugs, resulting in effective therapy of MDR in solid tumors.

Keywords

Anticancer Drug Multidrug Resistance Maximum Tolerate Dose Liposomal Doxorubicin Residual Resistance Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahmad, I., Longenecker, M., Samuel, J., and Allen, T. M., 1993, Antibody-targeted delivery of doxorubicin entrapped in sterically stabilzed liposomes can eradicate lung cancer in mice, Cancer Res., 53:1484.PubMedGoogle Scholar
  2. Alahari, S.K., Dean, N. M., Fisher, M. H., Delong, R., Manoharan, M, Tivel, K. L., and Juliano, R. L., 1996, Inhibition of expression of the multidrug resistance associated P-glycoprotein by phosphorothioate and 5’ cholesterol-conjugated phosphorothioate antisense oligonucleotides, Mol. Pharmacol., 50:808.PubMedGoogle Scholar
  3. Allen, T. M., and Hansen, C, 1991, Pharmacokinetics of stealth versus conventional liposomes: effect of dose, Biochim. Biophys. Acta, 1068:133.PubMedCrossRefGoogle Scholar
  4. Almquist, K. C, Loe, D. W., Hipfner, D. R., Mackie, J. E., Cole, S. P., and Deeley, R. G., 1995, Characterization of the M(r) 190,000 multidrug resistance protein (MRP) in drug selected and transfected human tumor cell, Cancer Res., 55:102.PubMedGoogle Scholar
  5. Batist, G., Tulpule, A., Sinha, B. K., Kakti, A. G., Myers, C. E., and Cowan, K. H., 1986, Overexpression of a novel anionic glutathione transferase in multidrug resistant human breast cancer cells, J Biol Chem., 33:15544.Google Scholar
  6. Boote D.J., Dennis I.F., Twentyman P.R., Osborne R.J., Laburte C, Hensel S., et al., 1996, Phase I study of etoposide with PSC-833 as a modulator of multidrug resistance in patients with cancer, J. Clin. Oncol., 14:610.PubMedGoogle Scholar
  7. Chan, H. S., Thorner, P. S., Haddad, G., DeBoer, G., Gallie, B. L., and Ling, V., 1993, Multidrug resistance in cancers of childhood: clinical relevance and circumvention, Cancer Res., 41:1967.Google Scholar
  8. Chan, H. S., Thorner, P., Haddad, G., and Ling, V., 1990, Immunohistochemical detection of P-glycoprotein: prognostic correlation in soft tissue sarcoma of childhood, J. Clin. Oncol, 8:689.PubMedGoogle Scholar
  9. Choice, E., Masin, D., Bally, M. B., Meloche, M., and Madden, T. D., 1995, Liposomal cyclosporine. Comparison of drug and lipid carrier pharmacokinetics and biodistribution, Transplantation, 60:1006.PubMedGoogle Scholar
  10. Cole, S.P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C, Stewart, A. J., Kurz, E. U., Duncan, A. M., and Deeley, R. G., 1992, Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line, Science, 258:1650.PubMedCrossRefGoogle Scholar
  11. Colombo T., Paz O. G., and D’lncalci M., 1996, Distribution and activity of doxorubicin combined with SDZ PSC 833 in mice with P388 and P388/DOX leukemia, Br. J. Cancer, 73:866.PubMedCrossRefGoogle Scholar
  12. Erlichman C, Moore M., Thiessen J., De Angelis C, Goodman P., and Manzo J., 1994, A Phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR), Anti-Cancer Drugs, 5:42.CrossRefGoogle Scholar
  13. Fan, D., Bucana, CD., O’Brian, C. A., Zwelling, L.A., Seid, C, and Fidler, I.J., 1990, Enhancement of murine tumor cell sensitivity to adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes, Cancer Res., 50:3619.PubMedGoogle Scholar
  14. Fan D., Beltran P.J., and O’Brien CA., 1994, Reversal of multidrug resistance, in: “Reversal of Multidrug Resistance in Cancer”, J. A. Kellen (Ed.), CRC Press, Boca Raton.Google Scholar
  15. Forssen, E. A., Male-Brune, R., Adler-Moore, J. P., Lee, M. J., Schmidt, P. G., Krasieva, T. B., Shimizu, S., and Tromberg, B. J., 1996, Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue, Cancer Res., 56:2066.PubMedGoogle Scholar
  16. Gabizon, A., 1992, Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long circulating liposomes, Cancer Res., 52:891.PubMedGoogle Scholar
  17. Gabizon, A., and Papahadjopolous, D., 1988, Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors, Proc. Natl. Acad. Sci. USA, 85:6949.PubMedCrossRefGoogle Scholar
  18. Gabizon, A., Barenholz, Y., and Bialer, M., 1993, Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethylene glycol-derivatized phospholipid: pharmacokinetic studies in rodents and dogs, Pharm. Res., 10:703.PubMedCrossRefGoogle Scholar
  19. Giaccone, G., Gazdar, A. F., Beck, H., Zunino, F., and Capranico, G., 1992, Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression, Cancer Res., 52:1666.PubMedGoogle Scholar
  20. Gokhale, P. C, Radhakrishnan, B., Husain, S. R., Abernethy, D. R., Sacher, R., Dritschilo, A., and Rahman, A., 1996, An improved method of encapsulation of doxorubicin in liposomes: pharmacological, toxicological, and therapeutic evaluation, Br. J. Cancer, 74:43.PubMedCrossRefGoogle Scholar
  21. Gonzalez O., Colombo T., De Fusco M., Imperatori L., Zucchetti M., and D’lncalci M., 1995, Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833, Cancer Chemother. Pharmacol, 36:335.PubMedCrossRefGoogle Scholar
  22. Grant, C E., Valdimarsson, G., Hipmer, D. R., Almquist, K. C, Cole, S. P., and Deeley, R. G., 1994, Overexpression of multidrug resistance-associated protein increases resistance to natural product drugs, Cancer Res., 54:357.PubMedGoogle Scholar
  23. Haak, H. R., van Seters, A. P., Moolenaar, A. J., and Fleuren, G. J., 1993, Expression of P-glycoprotein in relation to clinical manifestation, treatment and prognosis of adrenocortical cancer, Eur. J. Cancer, 29A:1036.PubMedCrossRefGoogle Scholar
  24. Haber, M., Norris, M. D., Kavallaris, M., Bell, D. R., Davey, R. A., White, L., and Stewart, B. W., 1989, Atypical multidrug resistance in a therapy-induced drug resistant human leukemia cell line (LALW-2): resistance to vinca alkaloids independent of P-glycoprotein, Cancer Res., 49:5281.PubMedGoogle Scholar
  25. Hansen, C. B., Kao, G. Y., Moase, E. H., Zalipsky, S., and Allen, T. M., 1995, Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison, and optimization of coupling procedures, Biochim. Biophys. Acta, 1239:133.PubMedCrossRefGoogle Scholar
  26. Hu, Y. P., Henry-Toulme, N., and Robert, J., 1995, Failure of liposome encapsulation of doxorubicin to circumvent multidrug resistance in an in vitro model of rat glioblastoma cells, Eur. J. Cancer, 31A:389.PubMedCrossRefGoogle Scholar
  27. Huang, S. K., Mayhew, E., Gilani, S., Lasic, D. D., Martin, F. J., and Papahadjopoulos, D., 1992, Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma, Cancer Res., 52:6744.Google Scholar
  28. Juliano, R. L., and Ling, V., 1976, A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants, Biochem Biophys Acta., 455:152.PubMedCrossRefGoogle Scholar
  29. Kartner, N., Riordan, J. R., and Ling, V., 1983, Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines, Science, 221:1285.PubMedCrossRefGoogle Scholar
  30. Keller R.P., Altermatt H.J., Donatsch P., Zihlmann H., Laissue J.A., and Hiestand P.C., 1992, Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity, Int. J. Cancer, 51:433.PubMedCrossRefGoogle Scholar
  31. Keller R.P., Altermatt H.J., Nooter K., Poschmann G., Laissue J.A., Bollinger P., et al., 1992, SDZ PSC 833, a non-immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein mediated multidrug resistance of murine leukemia, Int. J. Cancer, 50:593.PubMedCrossRefGoogle Scholar
  32. Kiehntopf, M., Brach, M.A., Licht, T., Petschauer, S., Karawajew, L., Krischning, C, and Herrmann, F., 1994, Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells, EMBO J., 13:4645.PubMedGoogle Scholar
  33. Krishna, R., de Jong, G., and Mayer, L. D., 1997, Pulsed exposure of SDZ PSC 833 to multidrug resistant P388/ADR and MCF7/ADR cells in the absence of anticancer drugs can fully restore sensitivity to doxorubicin, Anticancer Res., 17:3329.PubMedGoogle Scholar
  34. Krishna, R., and Mayer, L.D., 1997, Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug resistant solid tumors, Cancer Res., 57:5246.PubMedGoogle Scholar
  35. Krishnamachary, N., and Center, M. S., 1992, Detection and characterization of membrane protein changes in multidrug resistant HL-60 cells, Oncology Res., 4:23.Google Scholar
  36. Lee, R.J., and Low, P.S., 1995, Folate-mediated tumor cell targeting of liposome-entrapped doxoubicin in vitro, Biochim. Biophys. Acta, 1233:134.PubMedCrossRefGoogle Scholar
  37. Ling, V., and Thompson, L. H., 1974, Reduced permeability in CHO cells as a mechanism of resistance to colchicine, J Cell Physiol., 83:103.PubMedCrossRefGoogle Scholar
  38. Lopes de Menezes, D. E., Pilarski, L. M., and Allen, T. M., 1995, Selective cytotoxicity of immunoliposomal doxorubicin to B lympocytes, Proc. AACR, 36:A1825.Google Scholar
  39. Ludescher, C, Hilbe, W., Eisterer, W., Preuss, E., Huber, C, Gotwald, M., Hofmann, J., and Thaler, J., 1993, Activity of P-Glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometry assay, J. Natl. Cancer Inst., 85:1751.PubMedCrossRefGoogle Scholar
  40. Marie, J., Faussat-Suberville, A., Zhou, D., and Zittoun, R., 1993, Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdrl expression, Leukemia, 7:825.PubMedGoogle Scholar
  41. Marjan, J., Charrios, G., Lopes de Menezes, D., and Allen, T. M., 1996, Antibody-mediated targeting of liposomal doxorubicin to lymphoblastic cells can reverse multidrug resistance, Proc. AACR, 37:A2103.Google Scholar
  42. Mayer L.D., Bally M.B., Cullis P.R., Wilson S.L., and Emerman J.T., 1990, Comparison of free and liposomal encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC1 15 murine mammary tumor, Cancer Lett., 53:183.PubMedCrossRefGoogle Scholar
  43. Mayer L.D., Tai L.C.L., Ko D.S.C., Masin D., Ginsberg R.S., Cullis P.R., et al., 1989, Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice, Cancer Res., 49:5922.PubMedGoogle Scholar
  44. Mayer, L. D., Masin, D., Nayar, R., Boman, N. L., and Bally, M. B., 1995, Pharmacology of liposomal vincristine in mice bearing L1210 ascitic and B16/BL6 solid tumors, Br. J. Cancer, 71:482.PubMedCrossRefGoogle Scholar
  45. Mayhew, E.G., Lasic, D., Babbar, S., and Martin, F J., 1992, Pharmacokinetics and antitumor activity of epirubicin encapsulated in long-circulating liposomes incorporating a polyethylene glycolderivatized phospholipid, Int. J. Cancer, 51:302.PubMedCrossRefGoogle Scholar
  46. Merlin, J. L., Marchai, S., Ramacci, C, Notter, D., and Vigneron, C, 1993, Antiproliferative activity of thermosensitive liposome-encapsulated doxorubicin combined with 43 degrees C hyperthermia in sensitive and multidrug resistant MCF7 cells, Eur. J. Cancer, 29A:2264.PubMedCrossRefGoogle Scholar
  47. Oudard, S., Thierry, A., Jorgensen, T. J., and Rahman, A., 1991, Sensitization of multidrug resistant colon cancer cells to doxorubicin encapsulated in liposomes, Cancer Chemother. Pharmacol, 28:259.PubMedGoogle Scholar
  48. Ouyang, C., Choice, E., Holland, J., Meloche, M., and Madden, T. M., 1995, Liposomal cyclosporine. Characterization of drug incorporation and interbilayer exchange, Transplantation, 60:999.PubMedGoogle Scholar
  49. Papahadjopoulos, D., Allen, T. M, Gabizon, A., Mayhew, E., Mathay, K., Huang, S. L., Lee, K.-D., Woodle, M. C, Lasic, D. D., Redemann, C, and Martin, F. J., 1991, Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl. Acad. Sci. USA, 88:11460.PubMedCrossRefGoogle Scholar
  50. Pourtier-Manzanedo A., Didier A., Froidevaux S., and Loor F., 1995, Lymphotoxicity and myelotoxicity of doxorubicin and SDZ PSC 833 combined chemotherapies for normal mice, Toxicology, 99:207.PubMedCrossRefGoogle Scholar
  51. Rahman, A., Husain, S. R., Siddiqui, J., Verma, M., Agresti, M, Center, M., Safa, A. R., and Glazer, R. I., 1992, Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells, J. Natl. Cancer Inst., 84:1909.PubMedCrossRefGoogle Scholar
  52. Riordan, J. R., and Ling, V., 1979, Purification of P-glycoprotein from plasma membrane vesicles of Chinese hamster ovary cell mutants with reduced colchicine permeability, J Biol Chem., 254:12701.PubMedGoogle Scholar
  53. Ross, D. D., Wooten, P. J., Sridhara, R., Ordonez, J. V., Lee, E. J., and Schiffer, C. A., 1993, Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia, Blood, 82:1288.PubMedGoogle Scholar
  54. Scheithauer, W., Schenk, T., and Czejka, M., 1993, Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil, Br. J. Cancer, 68:8.PubMedCrossRefGoogle Scholar
  55. Sela, S., Husain, S. R., Pearson, J. W., Longo, D. L., and Rahman, A., 1995, Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil, J. Natl. Cancer Inst., 87:123.PubMedCrossRefGoogle Scholar
  56. Slater, L. M., Murray, S. L., Wetzel, M. W., Sweet, P., and Stupeck, M., 1986, Verapamil potentiation of VP-16-213 in acute lymphatic leukemia and reversal of pleiotropic drug resistance, Cancer Chemother. Pharmacol, 16:50.PubMedCrossRefGoogle Scholar
  57. Storm, G., Bakker-Woudenberg, I. A., Woodle, M. C, Blume, G., Nassander, U. K., Vingerhoeds, M. H., Haisma, H., and Crommelin, D. J. A., 1994, Liposomal drug delivery: possibilities for manipulation, in Targeting of drugs 4: Advances in System Constructs, G. Gregoriadis, B. McCormack and G. Poste (Eds.), Plenum Press, New York.Google Scholar
  58. Sugawara, I., 1990, Expression and functions of P-glycoprotein (mdrl gene product) in normal and malignant tissues, Acta Pathol. Jap., 40:545.Google Scholar
  59. Suzuki, S., Inoue, K., Hongoh, A., Hashimoto, Y., and Yamazoe, Y., 1997, Modulation of doxorubicin resistance in a doxorubicin-resistant human leukemia cell by an immunoliposome targeting transferring receptor, Br. J. Cancer, 76:83.PubMedCrossRefGoogle Scholar
  60. Thierry, A. R., Dritschilo, A., and Rahman, A., 1992, Effect of liposomes on P-glycoprotein function in multidrug resistant cells, Biochem. Biophys. Res. Comm., 187:1098.PubMedCrossRefGoogle Scholar
  61. Thierry, A. R., Rahman, A., and Dritschilo, A., 1993, Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligonucleotides, Biochem. Biophys. Res. Comm., 190:952.PubMedCrossRefGoogle Scholar
  62. Thierry, A. R., Rahman, A., and Dritschilo, A., 1994, A new procedure for the preparation of liposomal doxorubicin: biological activity in multidrug-resistant tumor cells. Cancer Chemother. Pharmacol, 35:84.PubMedCrossRefGoogle Scholar
  63. Tsuruo, T., Iida, H., Kitatani, Y., Yokota, K., Tsukagoshi, S., and Sakurai, Y., 1982, Enhancement of vincristine-and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin, Biochem Pharmacol, 31:3138.PubMedCrossRefGoogle Scholar
  64. Tsuruo, T., Iida, H., Naganuma, K., Tsukagoshi, S., and Sakurai, Y., 1983, Promotion of verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug, Cancer Res., 43:808.PubMedGoogle Scholar
  65. Tsuruo, T., Iida, H., Tsukagoshi, S., and Sakurai, Y., 1981, Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil, Cancer Res., 41:1967.PubMedGoogle Scholar
  66. Van Hossel Q.G.C.M., Steerenberg P.A., Crommelin D.J.A., van Dijk A., van Oort W., Klein S., et al., 1984, Reduced cardiotoxicity and nephrotoxicity with preservation of antitumor activity of DOX entrapped in stable liposomes in the LOU/M Ws1 rat, Cancer Res., 44:3698.Google Scholar
  67. Vergier, B., Cany, L., Bonnet, F., Robert, J., de Mascarel, A., and Coindre, J. M., 1993, Expression of MDR1/P-glycoprotein in human sarcomas, Br. J. Cancer, 68:1221.PubMedCrossRefGoogle Scholar
  68. Versantoort, C. H. M., Broxterman, H. J., Pinedo, H. M., de Vries, E. G. E., Feller, N., Kupier, C. M., and Lankelma, J., 1992, Energy-dependent processes involved in reduced drug accumulation in multidrug resistant human lung cancer cell lines without P-glycoprotein expression, Cancer Res., 52:17.Google Scholar
  69. Watanabe T., Tsuge H., Oh-hara T., Naito M., and Tsuruo T., 1995, Comparative study on reversal efficacy of SDZ PSC 833, cyclosproin A and verapamil on multidrug resistance in vitro and in vivo, Acta Oncologica, 34:235.PubMedCrossRefGoogle Scholar
  70. Webb, M. S., Wheeler, I. J., Bally, M. B., and Mayer, L. D., 1995, The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery, Biochim. Biophys. Acta, 1238:147.PubMedCrossRefGoogle Scholar
  71. Williams, S.S., Alosco, T. R., Mayhew, E., Lasic, D. D., Martin, F. J., and Bankert, R. B., 1993, Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes, Cancer Res., 53:3964.PubMedGoogle Scholar
  72. Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., and Jain, R. K., 1994, Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft, Cancer Res., 54:3352.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Rajesh Krishna
    • 1
    • 2
  • Lawrence D. Mayer
    • 1
    • 2
  1. 1.Department of Advanced TherapeuticsBC Cancer AgencyVancouverCanada
  2. 2.Faculty of Pharmaceutical SciencesUniversity of British ColumbiaVancouverCanada

Personalised recommendations